| Literature DB >> 33600704 |
Kitae Kim1, Beom Joon Kim1, Jaewon Huh2, Seong Kyu Yang1, Mi Hwa Yang1, Moon-Ku Han1, Cheolkyu Jung3, Byung Se Choi3, Jae Hyoung Kim3, Hee-Joon Bae1.
Abstract
BACKGROUND ANDEntities:
Keywords: DWI-negative stroke; Delayed DWI lesion; Diffusion magnetic resonance imaging; Stroke
Year: 2021 PMID: 33600704 PMCID: PMC7900394 DOI: 10.5853/jos.2020.02110
Source DB: PubMed Journal: J Stroke ISSN: 2287-6391 Impact factor: 6.967
Baseline characteristics and outcomes of study subjects (n=694)
| Variable | Whole subjects (n=694) | Model development set (n=488) | External validation set (n=206) | |
|---|---|---|---|---|
| Male sex | 404 (58.2) | 285 (58.4) | 119 (57.8) | 0.88 |
| Age at arrival (yr) | 62.9±13.7 | 62.7±13.4 | 63.4±14.4 | 0.52 |
| Height (cm) | 163.7±8.5 | 163.5±8.5 | 164.2±8.6 | 0.32 |
| Weight (kg) | 65.3±11.6 | 65.1±11.3 | 65.6±12.2 | 0.60 |
| BMI (kg/cm2) | 24.3±3.2 | 24.3±3.1 | 24.2±3.4 | 0.91 |
| Initial NIHSS[ | 0.17 | |||
| 0 | 440 (63.4) | 318 (65.2) | 122 (59.2) | |
| 1 | 114 (16.4) | 75 (15.4) | 39 (18.9) | |
| ≥2 | 140 (20.2) | 95 (19.5) | 45 (21.8) | |
| Discharge NIHSS[ | 0.69 | |||
| 0 | 517 (74.5) | 359 (73.6) | 158 (76.7) | |
| 1 | 99 (14.3) | 72 (14.8) | 27 (13.1) | |
| ≥2 | 78 (11.2) | 57 (11.7) | 21 (10.2) | |
| Pre-stroke mRS[ | 0.89 | |||
| 0 | 649 (93.5) | 456 (93.4) | 193 (93.7) | |
| 1 | 23 (3.3) | 16 (3.3) | 7 (3.4) | |
| ≥2 | 22 (3.2) | 16 (3.3) | 6 (2.9) | |
| Post-stroke mRS[ | 0.65 | |||
| 0 | 477 (68.7) | 332 (68.0) | 145 (70.4) | |
| 1 | 127 (18.3) | 89 (18.2) | 38 (18.4) | |
| ≥2 | 90 (13.0) | 67 (13.2) | 23 (11.2) | |
| Initial systolic BP | 154.3±27.1 | 154.7±27.2 | 153.4±26.8 | 0.57 |
| Initial diastolic BP | 85.5±16.2 | 85.8±16.5 | 84.9±15.5 | 0.49 |
| Clear onset | 563 (81.1) | 392 (80.3) | 171 (83.0) | 0.41 |
| Early neurologic deterioration | 23 (3.3) | 20 (4.1) | 3 (1.5) | 0.12 |
| Dysarthria | 308 (44.4) | 210 (43.0) | 98 (47.6) | 0.31 |
| Subjective hemiparesis | 368 (53.0) | 267 (54.7) | 101 (49.0) | 0.20 |
| Side of hemiparesis | 0.23 | |||
| None | 326 (47.0) | 221 (45.3) | 105 (51.0) | |
| Left | 191 (27.5) | 134 (27.5) | 57 (27.7) | |
| Right | 177 (25.5) | 133 (27.3) | 44 (21.4) | |
| Objective hemiparesis | 37 (5.3) | 24 (4.9) | 13 (6.3) | 0.57 |
| Objective arm weakness (MRC[ | ||||
| 5 | 640 (92.2) | 452 (92.6) | 188 (91.3) | 0.76 |
| <5 | 54 (7.8) | 36 (7.4) | 18 (8.7) | |
| Objective leg weakness (MRC[ | ||||
| 5 | 628 (90.5) | 439 (90.0) | 189 (91.7) | 0.37 |
| <5 | 66 (9.5) | 49 (10.0) | 17 (8.3) | |
| Dizziness | 164 (23.6) | 104 (21.3) | 60 (29.1) | <0.05 |
| Veering tendency | 65 (9.4) | 42 (8.6) | 23 (11.2) | 0.36 |
| Ataxia | 31 (4.5) | 23 (4.7) | 8 (3.9) | 0.78 |
| Hypesthesia | 138 (19.9) | 99 (20.3) | 39 (18.9) | 0.76 |
| Paresthesia | 82 (11.8) | 57 (11.7) | 25 (12.1) | 0.97 |
| Paresthesia & hypesthesia, simultaneously | 34 (4.9) | 22 (4.5) | 12 (5.8) | 0.59 |
| Aphasia | 42 (6.1) | 31 (6.4) | 11 (5.3) | 0.74 |
| Diplopia | 21 (3.0) | 17 (3.5) | 4 (1.9) | 0.40 |
| Duration | ||||
| >24 hr | 25 (3.6) | 22 (4.5) | 3 (1.4) | 0.09 |
| ≥1 and <24 hr | 329 (47.4) | 224 (45.9) | 105 (51.0) | |
| ≥10 min and <1 hr | 157 (22.6) | 116 (23.8) | 41 (19.9) | |
| <10 min | 105 (15.1) | 77 (15.8) | 28 (13.6) | |
| No data | 78 (11.2) | 49 (10.0) | 29 (14.1) | |
| Time from the first symptom onset to the initial MR image (hr) | 4.4 (2.0–10.5) | 4.5 (1.9–10.6) | 4.1 (2.2–10.2) | <0.05 |
| Time from the first symptom onset to the follow-up MR image (hr) | 61.0 (45.9–83.5) | 65.5 (49.3–89.1) | 50.7 (41.3–69.5) | <0.05 |
| Time from the initial MR image to the follow-up MR image (hr) | 51.5 (40.6–69.9) | 55.4 (43.0–75.1) | 44.8 (37.0–58.1) | <0.05 |
| Hypertension | 432 (62.2) | 311 (63.7) | 121 (58.7) | 0.25 |
| Diabetic mellitus | 164 (23.6) | 119 (24.4) | 45 (21.8) | 0.53 |
| Hyperlipidemia | 263 (37.9) | 178 (36.5) | 85 (41.3) | 0.27 |
| Atrial fibrillation | 61 (8.8) | 46 (9.4) | 15 (7.3) | 0.44 |
| Smoking | 0.83 | |||
| Current | 155 (22.3) | 112 (23.0) | 43 (20.9) | |
| Ex-smoker | 118 (17.0) | 83 (17.0) | 35 (17.0) | |
| None | 421 (60.7) | 293 (60.0) | 128 (62.1) | |
| Serum creatinine (mg/dL) | 0.88±0.50 | 0.88±0.53 | 0.89±0.44 | 0.78 |
| Hemoglobin (g/dL) | 13.9±1.7 | 13.9±1.7 | 13.9±1.6 | 0.79 |
| Total cholesterol level >240 mg/dL | 168.1±38.4 | 169.2±38.4 | 165.3±38.3 | 0.21 |
| Follow-up positive-conversion rate | 156 (22.5) | 111 (22.7) | 45 (21.8) | 0.87 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). Calculated using two-sample t-test for continuous variables or chi-square test for categorical variables.
BMI, body mass index; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; BP, blood pressure; MRC, Medical Research Council; MR, magnetic resonance.
The Neurological Stroke Scale measures stroke-related deficits, the score ranges from 0 to 42 with higher scores indicating more severe stroke;
The mRS score measures global disability and ranges from 0 (no symptoms) to 6 (death);
The Medical Research Council grade measures muscle power, the score ranges from 0 to 5 with lower scores indicating more weakness.
Figure 1.Hazard curves for 1-year stroke recurrence, all-cause mortality, and composite vascular outcome according to the presence of delayed diffusion-weighted imaging (DWI) lesions. Survival curves for (A) recurrent stroke, (B) all-cause mortality, and (C) composite vascular outcome by the presence of delayed DWI lesion. All P<0.01 using log-rank test. Data were adjusted for age, atrial fibrillation, smoking, pre-stroke dependency, objective hemiparesis, high cholesterol, National Institutes of Health Stroke Scale score, and high systolic blood pressure. Calculated using the log-rank test for P-value and Cox regression test for the adjusted hazard ratio (aHR). CI, confidence interval.
Full models for the effects of positive conversion and covariates in recurrent stroke, mortality, and composite vascular outcome
| Outcome | Positive-conversion and covaries | Adjusted OR (95% CI) |
|---|---|---|
| Recurrent stroke | DWI-positive conversion | 3.12 (1.56–6.26) |
| Age | 1.03 (1.01–1.06) | |
| Male sex | 1.10 (0.57–2.11) | |
| Atrial fibrillation | 0.77 (0.30–1.99) | |
| Smoking | 3.13 (1.25–7.69) | |
| Pre-stroke dependency[ | 1.07 (0.69–1.66) | |
| Objective hemiparesis | 1.11 (0.60–2.06) | |
| High cholesterol[ | 0.71 (0.09–5.46) | |
| NIHSS score | 1.07 (0.96–1.20) | |
| High systolic BP[ | 1.01 (1.00–1.02) | |
| All-cause mortality | DWI-positive conversion | 9.04 (2.23–36.04) |
| Age | 1.10 (1.04–1.17) | |
| Male sex | 12.34 (1.32–115.38) | |
| Atrial fibrillation | 0.02 (0.00–1.34) | |
| Smoking | 1.10 (0.32–3.84) | |
| Pre-stroke dependency[ | 1.83 (0.78–4.28) | |
| Objective hemiparesis | 0.44 (0.13–1.51) | |
| High cholesterol[ | 4.71 (0.42–52.84) | |
| NIHSS score | 1.18 (0.99–1.40) | |
| High systolic BP[ | 1.01 (0.99–1.03) | |
| Composite vascular outcome | DWI-positive conversion | 4.03 (2.16–7.51) |
| Age | 1.04 (1.02–1.06) | |
| Male sex | 1.29 (0.60–2.40) | |
| Atrial fibrillation | 0.49 (0.19–1.26) | |
| Smoking | 2.20 (1.04–4.61) | |
| Pre-stroke dependency[ | 1.11 (0.76–1.62) | |
| Objective hemiparesis | 0.88 (0.50–1.54) | |
| High cholesterol[ | 0.95 (0.22–4.17) | |
| NIHSS score | 1.11 (1.02–1.20) | |
| High systolic BP[ | 0.99 (0.98–1.00) |
Calculated using Cox regression test for adjusted hazard ratio (adjusted for age, atrial fibrillation, smoking, pre-stroke dependency, objective hemiparesis, high cholesterol, NIHSS score, and high systolic BP).
OR, odds ratio; CI, confidence interval; DWI, diffusion-weighted imaging; NIHSS, National Institutes of Health Stroke Scale; BP, blood pressure.
The pre-stroke dependency was defined as a modified Rankin Scale score of 2 to 5 before the onset of current stroke;
High cholesterol was defined as total levels higher than 240 mg/dL;
High systolic BP was defined as systolic BP more than or equal to 160 mm Hg.
Significant clinical characteristics by groups according to the presence of delayed DWI lesions
| Variable | Follow-up DWI-negative (n=377) | Follow-up positive-conversion (n=111) | OR on univariable analysis (95% CI) | OR on multivariable analysis (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Basic characteristics | |||||||
| Male sex | 219 (58.1) | 66 (59.5) | 0.80 | 1.06 (0.69–1.63) | – | ||
| Age at arrival (yr) | 62.8±13.5 | 62.3±13.4 | 0.72 | 1.00 (0.98–1.01) | – | ||
| Height (cm) | 163.4±8.5 | 163.8±8.4 | 0.88 | 1.00 (0.98–1.03) | 1.00 (0.96–1.05) | ||
| Weight (kg) | 65.2±11.2 | 64.9±11.8 | 0.61 | 1.00 (0.98–1.02) | 0.99 (0.97–1.02) | ||
| Body mass index (kg/m2) | 24.3±3.1 | 24.1±3.2 | 0.48 | 0.98 (0.91–1.05) | 0.98 (0.91–1.04) | ||
| Medical histories | |||||||
| Hypertension | 238 (63.1) | 73 (65.8) | 0.50 | 1.12 (0.72–1.76) | 1.18 (0.74–1.90) | ||
| Diabetic mellitus | 94 (24.9) | 25 (22.5) | 0.64 | 0.88 (0.52–1.43) | 0.89 (0.52–1.46) | ||
| Hyperlipidemia | 138 (36.6) | 40 (36.0) | 0.94 | 0.98 (0.62–1.51) | 0.98 (0.63–1.53) | ||
| Atrial fibrillation | 20 (5.3) | 26 (23.4) | <0.05 | 5.46 (2.92–10.35) | 6.17 (3.23–12.01) | ||
| Habitual smoking (current or ex-smoker) | 131 (34.7) | 64 (57.7) | <0.05 | 1.47 (1.15–1.88) | 3.76 (2.19–6.63) | ||
| Pre-stroke mRS[ | 0 (0–0) | 0 (0–0) | <0.05 | 1.55 (1.11–2.15) | 1.62 (1.15–2.27) | ||
| 0 | 358 (95.0) | 98 (88.3) | – | – | – | ||
| 1 | 11 (2.9) | 5 (4.5) | – | – | – | ||
| ≥2 | 8 (2.1) | 8 (7.2) | – | – | – | ||
| Presenting neurologic deficits | |||||||
| Clear onset | 307 (81.4) | 85 (76.6) | 0.15 | 0.75 (0.45–1.26) | 0.67 (0.38–1.17) | ||
| Early neurologic deterioration | 4 (1.1) | 16 (14.4) | <0.05 | 15.71 (5.61–55.80) | 15.10 (5.71–47.66) | ||
| Dysarthria | 149 (39.5) | 61 (55.0) | 0.08 | 1.87 (1.22–2.87) | 1.52 (0.96–2.42) | ||
| Subjective hemiparesis | 196 (52.0) | 71 (64.0) | 0.05 | 1.64 (1.06–2.55) | 1.60 (1.00–2.58) | ||
| Objective hemiparesis | 11 (2.9) | 13 (11.7) | <0.05 | 4.41 (1.92–10.35) | 4.39 (1.90–10.32) | ||
| Objective arm weakness | 22 (5.8) | 14 (12.6) | 0.12 | 2.33 (1.13–4.68) | 1.85 (0.83–3.99) | ||
| Objective leg weakness | 29 (7.7) | 20 (18) | <0.05 | 2.64 (1.41–4.85) | 2.72 (1.38–5.30) | ||
| Dizziness | 79 (21.0) | 25 (22.5) | 0.60 | 1.10 (0.65–1.81) | 1.16 (0.66–2.00) | ||
| Veering tendency | 32 (8.5) | 10 (9.0) | 0.57 | 1.07 (0.48–2.17) | 1.26 (0.54–2.76) | ||
| Ataxia | 18 (4.8) | 5 (4.5) | 0.69 | 0.94 (0.30–2.42) | 0.80 (0.23–2.28) | ||
| Hypesthesia | 74 (19.6) | 25 (22.5) | 0.17 | 1.19 (0.70–1.97) | 1.48 (0.84–2.56) | ||
| Paresthesia | 43 (11.4) | 14 (12.6) | 0.53 | 1.12 (0.57–2.09) | 1.25 (0.60–2.48) | ||
| Paresthesia & hypesthesia, simultaneously | 15 (4.0) | 7 (6.3) | 0.08 | 1.62 (0.61–3.96) | 2.36 (0.85–6.04) | ||
| Aphasia | 21 (5.6) | 10 (9.0) | 0.19 | 1.68 (0.74–3.60) | 1.80 (0.72–4.20) | ||
| Diplopia | 14 (3.7) | 3 (2.7) | 0.36 | 0.72 (0.16–2.26) | 0.53 (0.11–1.83) | ||
| Duration of symptoms (min) | – | – | <0.05 | 1.36 (1.15–1.64) | 2.17 (1.57–3.08) | ||
| ≥60 | 167 (44.3) | 79 (71.2) | – | – | – | ||
| 10–59 | 94 (24.9) | 22 (19.8) | – | – | – | ||
| <10 or unknown | 116 (30.8) | 10 (9.0) | – | – | – | ||
| Time from the first symptom onset to the initial MR image (hr) | 4.6 (1.9–10.8) | 3.5 (1.9–9.8) | 0.63 | 1.00 (0.99–1.00) | 1.00 (0.99–1.07) | ||
| Time from the first symptom onset to follow-up MR image (hr) | 64.4 (49.4–86.6) | 68.5 (47.8–95.0) | 0.87 | 1.00 (1.00–1.01) | 1.00 (1.00–1.01) | ||
| Time from initial MR image to follow-up MR image (hr) | 54.0 (43.7–70.3) | 61.1 (42.5–81.1) | 0.48 | 1.01 (1.00–1.01) | 1.00 (0.99–1.01) | ||
| Initial NIHSS[ | 0 (0–1) | 0 (0–2) | <0.05 | 1.60 (1.25–2.06) | 1.44 (1.08–1.91) | ||
| 0 | 262 (69.5) | 56 (50.5) | – | – | – | ||
| 1 | 53 (14.1) | 22 (19.8) | – | – | – | ||
| ≥2 | 62 (16.4) | 33 (29.7) | – | – | – | ||
| Laboratory abnormalities | |||||||
| Serum creatinine (mg/dL) | 0.88±0.57 | 0.87±0.34 | 0.96 | 0.99 (0.60–1.43) | 0.99 (0.58–1.45) | ||
| Hemoglobin (g/dL) | 13.9±1.8 | 14.1±1.5 | 0.35 | 1.06 (0.94–1.21) | 1.08 (0.93–1.26) | ||
| Total cholesterol level >240 mg/dL | 8 (2.1) | 10 (9.0) | <0.05 | 4.57 (1.76–12.25) | 4.70 (1.78–12.77) | ||
| Initial systolic BP per 1 mm Hg | 152.7±25.6 | 161.2±31.2 | <0.05 | 1.01 (1.00–1.02) | 1.01 (1.00–1.02) | ||
| Initial diastolic BP per 1 mm Hg | 85.2±15.7 | 88.0±18.9 | 0.15 | 1.01 (1.00–1.02) | 1.01 (1.00–1.02) | ||
Values are presented as number (%), mean±standard deviation, or median (interquartile range). Calculated by two-sample t-test for continuous variables or chi-square test for categorical variables.
DWI, diffusion-weighted imaging; OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; MR, magnetic resonance; NIHSS, National Institutes of Health Stroke Scale; BP, blood pressure.
The mRS measures global disability and ranges from 0 (no symptoms) to 6 (death);
The Neurological Stroke Scale measures stroke-related deficits; the score ranges from 0 to 42 with higher scores indicating more severe stroke.
DWI-CONVERSION score (0–39 points) to predict delayed DWI lesions
| Clinical factor | Points | β Regression coefficient (95% CI) |
|---|---|---|
| Total cholesterol level (mg/dL) | 1.27 (0.17 to 2.37) | |
| >240 | 4 | |
| ≤240 | 0 | |
| Blood pressure (mm Hg) | 0.36 (0.06 to 0.67) | |
| Systolic BP ≥180 or diastolic BP ≥110 | 2 | |
| 180> systolic BP ≥160 or 110> diastolic BP ≥100 | 1 | |
| Systolic B | 0 | |
| Symptom duration (min) | 0.70 (0.35 to 1.05) | |
| ≥60 | 4 | |
| 10–59 | 2 | |
| 0–9 or unclear | 0 | |
| Atrial fibrillation | 1.67 (0.95 to 2.39) | |
| Yes | 6 | |
| No | 0 | |
| Habitual smoking | 0.83 (0.33 to 1.32) | |
| Current or ex-smoker | 3 | |
| Never smoker | 0 | |
| Objective motor power | 0.60 (–0.39 to 1.59) | |
| MRC grade of arm <5 and MRC grade of leg <5, simultaneously | 2 | |
| Other | 0 | |
| Aphasia | 0.79 (–0.14 to 1.72) | |
| Yes (any type of aphasia) | 3 | |
| No | 0 | |
| Dysarthria and subjective hemiparesis | 1.27 (0.72 to 1.82) | |
| Dysarthria and subjective hemiparesis, simultaneously | 4 | |
| Other | 0 | |
| Veering tendency and time from first symptom onset to initial MRI (hr) | 0.57 (–0.29 to 1.42) | |
| Veering tendency and <96, simultaneously | 2 | |
| Other | 0 | |
| Sensory | 1.03 (–0.02 to 2.09) | |
| Paresthesia and hypesthesia, simultaneously | 3 | |
| Other | 0 | |
| Pre-stroke mRS[ | 0.52 (0.13 to 0.91) | |
| ≥2 | 6 | |
| 1 | 2 | |
| 0 | 0 |
DWI, diffusion-weighted imaging; CI, confidence interval; BP, blood pressure; MRC, Medical Research Council; MRI, magnetic resonance imaging; mRS, modified Rankin Scale.
mRS measures global disability and ranges from 0 (no symptoms) to 6 (death).
Observed incidence of DWI-positive conversion on follow-up MRI
| DWI-CONVERSION score | DWI-negative in follow-up (total cohort) | Positive conversion in follow-up (total cohort) | Observed risk (%) (derivation cohort) | Observed risk (%) (validation cohort) |
|---|---|---|---|---|
| 0–4 | 224 | 15 | 6.4 | 6.1 |
| 5–9 | 213 | 70 | 24.5 | 25.3 |
| ≥10 | 51 | 71 | 59.6 | 54.5 |
DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging.
Figure 2.Receiver operating characteristic (ROC) curve of diffusionweighted imaging (DWI)-CONVERSION score in the derivation and validation cohorts and the ABCD2 score in the validation cohort. The optimismcorrected c-statistic of the DWI-CONVERSION score based on 1,000 bootstrap replicates was 0.813 (95% confidence interval [CI], 0.769 to 0.856) in the derivation cohort and 0.808 (95% CI, 0.743 to 0.872) in the validation cohort, which is significantly higher than that for the ABCD2 score in the validation cohort (c-statistic=0.678; 95% CI, 0.590 to 0.765; P<0.01). AUC, area under the curve.